SG11202004332XA - Use of riluzole prodrugs to treat ataxias - Google Patents

Use of riluzole prodrugs to treat ataxias

Info

Publication number
SG11202004332XA
SG11202004332XA SG11202004332XA SG11202004332XA SG11202004332XA SG 11202004332X A SG11202004332X A SG 11202004332XA SG 11202004332X A SG11202004332X A SG 11202004332XA SG 11202004332X A SG11202004332X A SG 11202004332XA SG 11202004332X A SG11202004332X A SG 11202004332XA
Authority
SG
Singapore
Prior art keywords
ataxias
treat
riluzole prodrugs
riluzole
prodrugs
Prior art date
Application number
SG11202004332XA
Inventor
Vladimir Coric
Robert Berman
Melissa Beiner
Gilbert L'italien
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of SG11202004332XA publication Critical patent/SG11202004332XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
SG11202004332XA 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias SG11202004332XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US201862717948P 2018-08-13 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
SG11202004332XA true SG11202004332XA (en) 2020-06-29

Family

ID=66438598

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004332XA SG11202004332XA (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Country Status (13)

Country Link
US (3) US20210023061A1 (en)
EP (1) EP3706739A4 (en)
JP (2) JP7352542B2 (en)
KR (1) KR20200103658A (en)
CN (1) CN112292127A (en)
AU (1) AU2018364749C1 (en)
BR (1) BR112020009173A2 (en)
CA (1) CA3082096A1 (en)
IL (1) IL274532B1 (en)
MX (1) MX2020004678A (en)
PH (1) PH12020550583A1 (en)
SG (1) SG11202004332XA (en)
WO (1) WO2019094851A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62915B1 (en) 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Riluzole prodrugs and their use
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2023081859A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208615T1 (en) 1993-07-09 2001-11-15 Scherer Corp R P METHOD FOR PRODUCING FREEZE-DRIED MEDICINAL DOSAGE FORMS
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
EP1001748B1 (en) 1997-07-25 2006-04-19 Alpex Pharma S.A. A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
ID29270A (en) 1998-11-20 2001-08-16 Rtp Pharma Inc MICRO PARTICLES THAT ARE STABILIZED BY PHOSPHOLIPIDS THAT CAN SPREAD
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
JP2005508939A (en) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド Composition having combined immediate release and sustained release characteristics
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (en) 2005-12-27 2011-12-06 Jubilant Organosys Ltd pharmaceutical composition that dissolves in the mouth and process for the preparation thereof
CN101686942B (en) 2007-06-27 2012-09-26 韩美药品株式会社 Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
JP2011516489A (en) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ Treatment of disease-induced ataxia and ataxia imbalance
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
RS62915B1 (en) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Riluzole prodrugs and their use

Also Published As

Publication number Publication date
NZ765220A (en) 2023-11-24
PH12020550583A1 (en) 2021-05-31
KR20200103658A (en) 2020-09-02
JP7352542B2 (en) 2023-09-28
CN112292127A (en) 2021-01-29
AU2018364749A1 (en) 2020-07-02
US20230390252A1 (en) 2023-12-07
US20230355592A1 (en) 2023-11-09
MX2020004678A (en) 2020-08-13
JP2021502392A (en) 2021-01-28
CA3082096A1 (en) 2019-05-16
BR112020009173A2 (en) 2020-11-03
EP3706739A4 (en) 2021-08-04
IL274532A (en) 2020-06-30
AU2018364749B2 (en) 2023-11-09
EP3706739A1 (en) 2020-09-16
IL274532B1 (en) 2024-01-01
JP2023175823A (en) 2023-12-12
WO2019094851A1 (en) 2019-05-16
AU2018364749C1 (en) 2024-02-15
US20210023061A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
HUE058184T2 (en) Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL278080B (en) Riluzole prodrugs and their use
IL274532A (en) Use of riluzole prodrugs to treat ataxias
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
IL252285B (en) Sublingual formulation of riluzole
IL271164A (en) Use of vibegron to treat overactive bladder
HK1248139A1 (en) Inhibition of olig2 activity
IL268048A (en) Salts and prodrugs of 1-methyl-d-tryptophan
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
IL266087A (en) Use of itolizumab to reduce phosphorylation of cd6
HK1256902A1 (en) Prodrugs of chlorokynurenines
IL268550B (en) Purification of pleuromutilin
HK1258512A1 (en) Prodrugs of fencamfamine
PT3393517T (en) Treatment of moderate to severe influenza
GB2537419B (en) Accumulation of floating-point values
GB2528112B (en) Improvements relating to inhibition of corrosion
IL253231B (en) Use of bgp15 to treat familial dysautonomia
PT3689913T (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
GB201417347D0 (en) Prodrugs of delanzomib
GB201417348D0 (en) Prodrugs of lxazomib